<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="84798"><DrugName>human immunoglobulin (pH4, intravenous, immunoglobulin G deficiency/autoimmune diseases), Shenzhen Weiwu Guangming Biological Products</DrugName><DrugSynonyms><Name><Value>human immunoglobulin (pH4, intravenous, immunoglobulin G deficiency/autoimmune diseases), Shenzhen Weiwu Guangming Biological Products</Value></Name></DrugSynonyms><CompanyOriginator id="1041544">Shenzhen Weiguang Biological Products Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1041544">Shenzhen Weiguang Biological Products Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1041544" type="Company"><TargetEntity id="5000536810" type="organizationId">Shenzhen Weiguang Biological Products Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1133" type="ciIndication"><TargetEntity id="10043561" type="MEDDRA"></TargetEntity><TargetEntity id="D011697" type="MeSH"></TargetEntity><TargetEntity id="-241656606" type="omicsDisease"></TargetEntity><TargetEntity id="1491" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2511" type="ciIndication"><TargetEntity id="D80.3" type="ICD10"></TargetEntity><TargetEntity id="D017099" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="36" type="ciIndication"><TargetEntity id="10061664" type="MEDDRA"></TargetEntity><TargetEntity id="D001327" type="MeSH"></TargetEntity><TargetEntity id="-2072222280" type="omicsDisease"></TargetEntity><TargetEntity id="729" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="780" type="ciIndication"><TargetEntity id="M30.3" type="ICD10"></TargetEntity><TargetEntity id="10023320" type="MEDDRA"></TargetEntity><TargetEntity id="D009080" type="MeSH"></TargetEntity><TargetEntity id="2331" type="ORPHANET"></TargetEntity><TargetEntity id="-1954143291" type="omicsDisease"></TargetEntity><TargetEntity id="1571" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Autoimmune disease - China - Dec-2004</FirstLaunched><FirstLaunched>Immunoglobulin G deficiency - China - Dec-2004</FirstLaunched><FirstLaunched>Kawasaki disease - China - Dec-2004</FirstLaunched><FirstLaunched>Thrombocytopenic purpura - China - Dec-2004</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1133">Thrombocytopenic purpura</Indication><Indication id="2511">Immunoglobulin G deficiency</Indication><Indication id="36">Autoimmune disease</Indication><Indication id="780">Kawasaki disease</Indication></IndicationsPrimary><ActionsPrimary><Action id="5731">Immunoglobulin agonist</Action></ActionsPrimary><Technologies><Technology id="1651">Blood constituents</Technology><Technology id="4">Immunoglobulin</Technology><Technology id="582">Antibody polyclonal</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><LastModificationDate>2013-09-24T17:35:50.000Z</LastModificationDate><ChangeDateLast>2013-09-24T00:00:00.000Z</ChangeDateLast><AddedDate>2013-05-01T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1041544"&gt;Shenzhen Weiwu Guangming Biological Products&lt;/ulink&gt; has  developed and launched an intravenous plasma-derived human immunoglobulin therapy, for the treatment of primary and secondary immunoglobulin G deficiency and autoimmune diseases (including thrombocytopenic purpura and Kawasaki disease). It was assumed that the product was launched in China shortly after its approval in 2004 [&lt;ulink linkType="Reference" linkID="1410638"&gt;1410638&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1409381"&gt;1409381&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1041544">Shenzhen Weiguang Biological Products Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>2004-12-31T00:00:00.000Z</StatusDate><Source id="1409381" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1041544">Shenzhen Weiguang Biological Products Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2511">Immunoglobulin G deficiency</Indication><StatusDate>2004-12-31T00:00:00.000Z</StatusDate><Source id="1409381" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1041544">Shenzhen Weiguang Biological Products Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1133">Thrombocytopenic purpura</Indication><StatusDate>2004-12-31T00:00:00.000Z</StatusDate><Source id="1409381" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1041544">Shenzhen Weiguang Biological Products Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="780">Kawasaki disease</Indication><StatusDate>2004-12-31T00:00:00.000Z</StatusDate><Source id="1409381" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1041544">Shenzhen Weiguang Biological Products Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2511">Immunoglobulin G deficiency</Indication><StatusDate>2004-12-31T00:00:00.000Z</StatusDate><Source id="1410638" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1041544">Shenzhen Weiguang Biological Products Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>2004-12-31T00:00:00.000Z</StatusDate><Source id="1410638" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1041544">Shenzhen Weiguang Biological Products Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="780">Kawasaki disease</Indication><StatusDate>2004-12-31T00:00:00.000Z</StatusDate><Source id="1410638" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1041544">Shenzhen Weiguang Biological Products Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1133">Thrombocytopenic purpura</Indication><StatusDate>2004-12-31T00:00:00.000Z</StatusDate><Source id="1410638" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01004"><Name>Immunoglobulin</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></drugRecordOutput>